Back

A novel protein signature from plasma extracellular vesicles for non-invasive differential diagnosis of idiopathic pulmonary fibrosis

Adduri, R. S.; Cai, K.; Alzate, K. V.; Vasireddy, R.; Miller, J. W.; Frias, S. P. d.; Frias, F. P. d.; Horimasu, Y.; Iwamoto, H.; Hattori, N.; Zhang, Y.; Gibson, K. F.; Pal, A. K.; Nicastro, D.; Li, L.; Cherian, S.; Sholl, L. M.; Schwartz, D. A.; Kass, D. J.; Rosas, I. O.; Konduru, N. V.

2021-05-14 respiratory medicine
10.1101/2021.05.07.21256811 medRxiv
Show abstract

BackgroundIdiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia of unknown etiology often leading to respiratory failure. Over half of IPF patients present with discordant features of usual interstitial pneumonia on high-resolution computed tomography at diagnosis which warrants surgical lung biopsy to exclude the possibility of other interstitial lung diseases (ILDs). Therefore, there is a need for non-invasive biomarkers for expediting the differential diagnosis of IPF. MethodsUsing mass spectrometry, we performed proteomic analysis of plasma extracellular vesicles (EVs) in a cohort of subjects with IPF, chronic hypersensitivity pneumonitis, nonspecific interstitial pneumonitis, and healthy subjects (HS). A five-protein signature was identified by lasso regression and was validated in an independent cohort using ELISA. We evaluated the concordance between plasma EV proteome and the lung transcriptome data. Lastly, we compared the molecular pathways overrepresented in IPF by differentially expressed proteins and transcripts from EVs and lung tissues, respectively. ResultsThe five-protein signature derived from mass spectrometry data showed area under the receiver operating characteristic curve of 0.915 (95%CI: 0.819-1.011) and 0.958 (95%CI: 0.882-1.034) for differentiating IPF from other ILDs and from HS, respectively. We also found that the EV protein expression profiles mirrored their corresponding mRNA expressions in IPF lungs. Further, we observed an overlap in the EV proteome- and lung mRNA-associated molecular pathways. ConclusionsWe discovered a plasma EV-based protein signature for differential diagnosis of IPF and validated this signature in an independent cohort. The signature needs to be tested in large prospective cohorts to establish its clinical utility.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
European Respiratory Journal
54 papers in training set
Top 0.1%
36.7%
2
Respiratory Research
19 papers in training set
Top 0.1%
18.1%
50% of probability mass above
3
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.1%
7.0%
4
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.3%
3.6%
5
ERJ Open Research
44 papers in training set
Top 0.3%
3.5%
6
Scientific Reports
3102 papers in training set
Top 42%
3.0%
7
BMJ Open Respiratory Research
32 papers in training set
Top 0.3%
2.0%
8
Clinical Immunology
21 papers in training set
Top 0.2%
1.8%
9
Frontiers in Immunology
586 papers in training set
Top 4%
1.7%
10
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.4%
1.7%
11
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.3%
12
Allergy
23 papers in training set
Top 0.4%
1.3%
13
PLOS ONE
4510 papers in training set
Top 61%
1.2%
14
Frontiers in Medicine
113 papers in training set
Top 5%
1.1%
15
Clinical and Translational Medicine
30 papers in training set
Top 0.7%
0.9%
16
Thorax
32 papers in training set
Top 0.7%
0.9%
17
iScience
1063 papers in training set
Top 28%
0.9%
18
Annals of Clinical and Translational Neurology
29 papers in training set
Top 1%
0.8%
19
eLife
5422 papers in training set
Top 59%
0.7%
20
Metabolites
50 papers in training set
Top 1%
0.7%
21
Signal Transduction and Targeted Therapy
29 papers in training set
Top 2%
0.7%
22
eBioMedicine
130 papers in training set
Top 5%
0.7%
23
American Journal of Physiology-Cell Physiology
34 papers in training set
Top 0.4%
0.7%
24
Critical Care
14 papers in training set
Top 0.7%
0.6%
25
JCI Insight
241 papers in training set
Top 9%
0.6%